Welcome to our dedicated page for Rani Therapeutics Holdings SEC filings (Ticker: RANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rani Therapeutics Holdings, Inc. (RANI) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Current Reports on Form 8-K and other key documents. These filings offer detailed information on material events affecting the clinical-stage biotherapeutics company, which focuses on oral delivery of biologics and drugs through its RaniPill® platform.
Rani’s recent Form 8-K filings have covered financial results and corporate updates, such as quarterly earnings releases where the company reports research and development expenses, general and administrative expenses, net loss figures and cash balances. These filings often incorporate press releases as exhibits, giving investors a structured view of the company’s operating performance and cash runway expectations.
Other 8-K filings document material agreements and capital markets transactions, including securities purchase agreements for private placements, registration rights agreements, amendments to loan and security agreements, and details of warrant issuances and debt conversions. Rani has also filed 8-Ks describing its Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd. and a collaboration with ProGen Co., Ltd., outlining upfront payments, milestone structures, royalty terms and shared development responsibilities for products that combine partner molecules with the RaniPill or RaniPill HC devices.
Filings further address governance and listing matters, such as notices from The Nasdaq Stock Market LLC regarding minimum bid price compliance, director appointments and resignations, and reconstitution of board committees. Through Stock Titan, users can review these filings alongside AI-powered summaries that highlight the main points of lengthy documents, helping to interpret complex sections on financing terms, collaboration structures and listing requirements without reading every line.
For investors researching RANI, this page is a central resource to examine 10-K and 10-Q reports when available, Form 8-K current reports and any future Form 4 insider transaction filings, with real-time updates from EDGAR and AI-generated explanations that clarify technical language and regulatory disclosures.
Rani Therapeutics Holdings, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 28, 2026. Investors will elect seven directors and ratify CBIZ CPAs P.C. as the independent registered public accounting firm for the year ending December 31, 2026.
The proxy statement details board independence, committee structures, risk oversight and prohibition on hedging, short sales and pledging. It also outlines executive pay, including salary cuts previously tied to financing, new option grants, a 2025 retention program, and severance and change in control protections for senior executives.
Rani Therapeutics Holdings, Inc. executive Alireza Javadi, Chief Technical Officer, reported his initial ownership of company securities. He directly holds 10,075 shares of Class A common stock, including 4,297 restricted stock units that vest in equal monthly installments from June 27, 2023 through March 27, 2027, subject to continued service.
He also holds several stock option awards over Class A common stock with exercise prices ranging from $0.6168 to $13.2100 per share and expirations between 2032 and 2035. One option grant is fully vested, while others vest monthly or in 25% annual installments over four-year periods beginning on December 27, 2023, March 21, 2024, and May 23, 2025, all contingent on his continued service.
Rani Therapeutics Holdings Inc ownership filing shows 0 shares beneficially owned by The Vanguard Group as reported in an amendment to a Schedule 13G/A. The filing explains an internal realignment effective January 12, 2026, causing certain Vanguard subsidiaries or business divisions to report separately and disaggregate prior beneficial ownership.
Rani Therapeutics Holdings is a clinical-stage biotherapeutics company developing the oral RaniPill capsule to replace injectable biologics, with both low-capacity GO and high-capacity HC versions. It focuses on obesity, immunology and partnered rare-disease programs and remains pre-revenue with ongoing operating losses.
As of June 30, 2025, non‑affiliate equity was valued at about $65.0 million based on a $0.51 share price. As of February 28, 2026, it had 99,721,927 Class A and 23,970,359 Class B shares outstanding. Certain Rani LLC holders may exchange units for 1,124,194 Class A shares.
In 2025, Rani strengthened liquidity through a $60.3 million private placement of Class A stock, pre-funded warrants and common warrants, a $3.0 million July offering, and warrant exercises totaling $8.4 million. It also eliminated debt by repaying the remaining $6.2 million loan principal plus associated interest and fees.
Pipeline highlights include initiating a Phase 1 trial of RT‑114, an oral GLP‑1/GLP‑2 dual agonist for obesity, advancing RT‑116 (oral semaglutide) toward Phase 1, and positive Phase 1 data for RT‑111 (oral ustekinumab). Rani entered a collaboration with Chugai for hemophilia product RT‑117, receiving a $10.0 million upfront payment and eligibility for substantial milestones and royalties, and a 50/50 collaboration with ProGen on RT‑114.
Rani Therapeutics reported fourth-quarter and full-year 2025 results while highlighting major strategic milestones. The company signed a collaboration and license agreement with Chugai worth up to $1.085 billion for oral delivery of a rare disease antibody using its RaniPill® platform and completed an oversubscribed private placement raising $60.3 million, including $6.0 million of debt conversion.
Cash, cash equivalents and marketable securities were $49.7 million as of December 31, 2025, up from $27.6 million a year earlier, and the company expects this, plus an anticipated Chugai milestone, to fund operations into the fourth quarter of 2027. Rani repaid all remaining Avenue debt in December 2025 and reported having no outstanding debt at year-end.
For 2025, contract revenue was $1.6 million, research and development expenses fell to $20.2 million and general and administrative expenses declined to $19.7 million, reflecting cost-containment efforts. Net loss narrowed to $41.0 million from $56.6 million in 2024, while the company advanced its pipeline with preclinical data for oral semaglutide and RT‑114 and initiation of a Phase 1 obesity study.
Investment Company, Inc., a Delaware investment adviser, reported beneficial ownership of 9,745,343 Class A shares of Rani Therapeutics Holdings, Inc., equal to 9.9% of the class as of 12/31/2025. The firm holds sole voting and dispositive power over these securities.
The position is held through three funds that own common shares, pre-funded warrants and warrants. These warrants may only be exercised so that total beneficial ownership does not exceed 9.99% of Rani’s outstanding shares. The filer certifies the stake is held in the ordinary course as a passive investment.
Rani Therapeutics Holdings, Inc. disclosed that SymBiosis Capital Partners, LLC has filed a Schedule 13G reporting a significant passive stake in the company’s Class A Common Stock. SymBiosis reports beneficial ownership of 6,300,000 shares, representing 6.5% of the class, as of an event date of 11/13/2025.
SymBiosis has sole voting and sole dispositive power over all 6,300,000 shares, with no shared voting or dispositive authority. The filing is made on a passive basis, with SymBiosis certifying that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Rani Therapeutics.
The Vanguard Group filed a Schedule 13G showing a passive ownership stake in Rani Therapeutics Holdings Inc. As of 12/31/2025, Vanguard beneficially owned 5,109,368 shares of Rani common stock, representing 5.23% of the class.
Vanguard reports shared voting power over 486,801 shares and shared dispositive power over all 5,109,368 shares, with no sole voting or dispositive power. The shares are held for Vanguard’s clients, and no single other person’s interest exceeds 5% of the class. Vanguard certifies the position is held in the ordinary course of business, not to change or influence control.
The filing notes an internal realignment effective 01/12/2026, after which certain Vanguard subsidiaries or business divisions may report beneficial ownership separately, while pursuing the same investment strategies as before.
Rani Therapeutics Holdings, Inc. obtained written consent from its majority voting stockholder as of November 21, 2025 to approve the issuance of shares underlying recently issued warrants and to adopt an amended and restated certificate of incorporation.
In an October 16, 2025 private placement, the company sold securities with gross proceeds of approximately $60.3 million, including common stock purchase warrants exercisable for up to 125,000,004 shares of Class A common stock at $0.48 per share, subject to stockholder approval under Nasdaq Listing Rule 5635(d). As of September 30, 2025, cash and cash equivalents were $4.1 million, and without the placement there was substantial doubt about continuing as a going concern.
The new charter, approved by the board and the majority holder, reduces Class B common stock voting rights from ten votes to one vote per share, eliminates separate Class B voting on specified matters, subjects the company to Delaware General Corporation Law Section 203, requires a two‑thirds stockholder vote to amend certain provisions, allows only the board or specified officers to call special meetings, eliminates a classified board structure, and disallows future stockholder action by written consent. The majority holder controlled about 65.5% of total voting power on the approval date, so no additional stockholder vote is being sought.